401. The use of fructosamine in cystic fibrosis-related diabetes (CFRD) screening.
- Author
-
Lam, Grace Y., Doll-Shankaruk, Michelle, Dayton, Jan, Rodriguez-Capote, Karina, Higgins, Trefor N., Thomas, Dylan, Mulchey, Kimberley, Smith, Maeve P., Brown, Neil E., Leung, Winnie M., and Estey, Mathew P.
- Subjects
- *
DIAGNOSIS of diabetes , *CYSTIC fibrosis , *FRUCTOSAMINE , *GLYCEMIC control , *BLOOD serum analysis - Abstract
Objective To determine whether serum fructosamine correlates with glycemic control and clinical outcomes in patients being screened for cystic fibrosis-related diabetes (CFRD). Methods Fructosamine and percent predicted forced expiratory volume in 1 s (FEV 1 ) were measured in patients undergoing a 2 h oral glucose tolerance test (OGTT) for CFRD screening. Fractional serum fructosamine (FSF) was calculated as fructosamine/total protein. Results FSF exhibited a positive correlation with 2 h OGTT results (r 2 = 0.3201, p = 0.009), and ROC curve analysis suggested that FSF can identify patients with an abnormal OGTT (AUC = 0.840, p = 0.0002). FSF also exhibited a negative correlation with FEV 1 (r 2 = 0.3732, p = 0.035). Patients with FSF ≥ 3.70 μmol/g had significantly lower FEV 1 (median 47%) compared to those with FSF < 3.70 μmol/g (median 90%; p = 0.015). Conclusions FSF correlated with both OGTT results and FEV 1 , and reliably identified patients with abnormal OGTT results. This simple blood test shows potential as an effective tool in CFRD screening. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF